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Abstract
Background: Globally ICUs are encountering emergence and spread of antibiotic-resistant pathogens and for
some pathogens there are few therapeutic options available.
Methods: Antibiotic in vitro susceptibility data of predominant ICU pathogens during 2000–2 were analyzed
using data from The Surveillance Network (TSN) Databases in Europe (France, Germany and Italy), Canada, and
the United States (US).
Results: Oxacillin resistance rates among Staphylococcus aureus isolates ranged from 19.7% to 59.4%. Penicillin
resistance rates among Streptococcus pneumoniae varied from 2.0% in Germany to as high as 20.2% in the US;
however, ceftriaxone resistance rates were comparably lower, ranging from 0% in Germany to 3.4% in Italy.
Vancomycin resistance rates among Enterococcus faecalis were ≤ 4.5%; however, among Enterococcus faecium
vancomycin resistance rates were more frequent ranging from 0.8% in France to 76.3% in the United States.
Putative rates of extended-spectrum β-lactamase (ESBL) production among Enterobacteriaceae were low, <6%
among Escherichia coli in the five countries studied. Ceftriaxone resistance rates were generally lower than or
similar to piperacillin-tazobactam for most of the Enterobacteriaceae species examined. Fluoroquinolone resistance
rates were generally higher for E. coli (6.5% – 13.9%), Proteus mirabilis (0–34.7%), and Morganella morganii (1.6–
20.7%) than other Enterobacteriaceae spp (1.5–21.3%). P. aeruginosa demonstrated marked variation in β-lactam
resistance rates among countries. Imipenem was the most active compound tested against Acinetobacter spp.,
based on resistance rates.
Conclusion: There was a wide distribution in resistance patterns among the five countries. Compared with
other countries, Italy showed the highest resistance rates to all the organisms with the exception of Enterococcus
spp., which were highest in the US. This data highlights the differences in resistance encountered in intensive care
units in Europe and North America and the need to determine current local resistance patterns by which to guide
empiric antimicrobial therapy for intensive care infections.
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Background
Antimicrobial resistance has emerged as an important fac-
tor in predicting outcomes and overall resource use after
infections in intensive care units (ICU) [1]. Globally ICUs
are encountering emergence and spread of antibiotic-
resistant pathogens. For some pathogens there are few
therapeutic options available, e.g., vancomycin-resistant
Enterococcus faecium. Awareness of these problems has
been underscored with data from a number of surveil-
lance studies aimed at improving the use of empiric ther-
apy. In the United States there have been several national
programs, which have focused on both the etiology of
infections and resistance patterns of nosocomial or ICU
infections including the National Nosocomial Infections
Surveillance (NNIS) [2] and more recently an ICU-specific
study examining the epidemiology of antimicrobial resist-
ance, Project ICARE [3,4]. Stephen et al. collected strains
from 28 ICUs from across the United States as part of the
SENTRY Antimicrobial Surveillance Program in 2001 [5].
European data on the antimicrobial resistance of ICU
pathogens has also been collected in several recent surveil-
lance studies. A large prevalence survey of nosocomial
infections in ICUs in 17 countries was published in 1995
[6], and more recently a number of nation-specific surveys
were reported [7-9]. Several key points emerge: first, anti-
microbial resistance among ICU pathogens is generally
increasing, but variations do exist among different coun-
tries, probably due to individual antimicrobial use pat-
terns; second, when new medical practices and alternative
antimicrobials are introduced changes in the dominant
microbial etiologies may emerge prompting novel
empiric selections; and third, the standards of hygiene
and infection control also vary across countries. Finally,
appropriate therapy of ICU infections directed by local
resistance data can have significant consequences for both
patient and the healthcare system. It is against this back-
ground that local resistance surveillance programs are of
most value in developing appropriate therapeutic guide-
lines for specific infections and patient types. For exam-
ple, the recent modification to the American Thoracic
Society guidelines for the treatment of hospital-acquired
pneumonia [10] considered contemporary resistance
data. Local surveillance data can be applied to other infec-
tions to assist in local formulary policy such as those gov-
erning treatment of nosocomial urinary tract infections
[11].
This study using TSN program reports the antimicrobial
resistance profiles of bacterial isolates from ICU patients
in five countries during the period 2000–2002. The rele-
vance of these recent nation-specific data will be discussed
on a country-by-country basis, as part of improving and
updating empiric therapeutic approaches to specific path-
ogens causing infections in the ICU setting according to
each country. These surveillance programs help to main-
tain current knowledge of susceptibilities and relevant
treatment options.
Methods
TSN Database – United States and Europe
TSN is a queriable, real-time database that electronically
assimilates daily antimicrobial susceptibility testing and
patient demographic data from a network of geographi-
cally dispersed laboratories in the United States (283 hos-
pital sites), France (63 hospital sites), Germany (169
hospital sites), Italy (48 hospital sites) and Canada (87
hospital sites) [12].
Laboratories included in TSN include those servicing uni-
versity, community, and private hospitals with bed sizes
ranging from 100 to >1000 beds. Routine diagnostic sus-
ceptibility testing results are collected daily from each par-
ticipating laboratory. The methods used by these
laboratories include VITEK (bioMérieux, St. Louis, MO),
MicroScan (Dade-Microscan, Sacramento, CA), Sceptor
and Pasco MIC/ID (Becton Dickinson, Sparks, MD) and
Etest (AB Biodisk, Solna, Sweden), as well as manual
broth microdilution MIC, disk diffusion and agar dilu-
tion. TSN reflects current testing in participant laborato-
ries and represents the data reported to physicians from
the respective laboratories [13].
Although some European countries have alternate break-
points, all data forwarded to TSN Databases are derived
from hospitals that utilized NCCLS standards and defini-
tions (United States, Canada, Italy, and Germany) [14] or
the Comité de L'Antibiogramme de La Societé Français de
Microbiologie (France) [15] thus standardizing datasets.
Results were interpreted as susceptible, intermediate (if
available), or resistant in TSN, based upon the NCCLS
interpretative guidelines in place during 2001 [16]. In
addition, a series of quality-control filters (i.e., critical rule
sets) were used in TSN to screen susceptibility test results
for patterns indicative of testing error and suspect results
were removed from analysis for laboratory confirmation.
In TSN, any result from the same patient with the same
organism identification and the same susceptibility pat-
tern received within five days was considered a repeat cul-
ture and was counted only once in the database.
Bacterial species and antimicrobials tested
For this study, data from TSN results for each individual
database from January 1, 2000 through to December 31,
2002 were included in the analysis to determine the pro-
portion of species and their susceptibility to antimicrobial
agents commonly tested in clinical laboratories through-
out the participating regions. Only isolates derived from
patients located in hospital ICUs were considered in the
analysis. Gram-positive species included in the analysisAnnals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
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were comprised of S. aureus, coagulase negative staphylo-
cocci, Enterococcus faecalis,Enterococcus faecium, Streptococ-
cus pyogenes, Streptococcus pneumoniae and viridans group
streptococci. Gram-negative species studied comprised
the predominantly encountered enteric species
(Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae,
Proteus mirabilis, Morganella morganii and Serratia
marcescens), and Pseudomonas aeruginosa and Acinetobacter
spp.
The antibiotics studied are listed in Tables 2,3,4,5. Among
E. coli, putative ESBL production was defined as those iso-
lates that were intermediate or resistant (non-susceptible)
to ceftazidime [17]. Given the large number of isolate
results included in the majority of analyses in this study,
statistical analysis was not performed, as even subtle dif-
ferences in percent resistance (<1%) to an antimicrobial
agent for any time period or demographic parameters
would be reported as highly significant (P <0.001).
Results
In vitro susceptibility data from over 220,000 isolates
from ICUs in five countries over the period 2000–2002
were assimilated. The most frequent species isolated from
infections in the ICU was S. aureus, being most common
in three of the five countries (Table 1). The oxacillin resist-
ance rates among S. aureus varied markedly across coun-
tries from 19.7% in Canada to 59.5% in Italy. E. coli
(7.7%–15.5%) and P. aeruginosa (10.8%–22.3%) were
the most frequent Gram-negative organisms encountered.
The Gram-positive genus Enterococcus, either as E. faecalis,
E. faecium or non-speciated isolates accounted for <10%
of isolates in most countries with E. faecalis being the most
common species <4.3%. Community-acquired respira-
tory pathogens such as Streptococcus pneumoniae and Hae-
mophilus influenzae were relatively uncommon in all five
countries.
Tables 2,3,4,5 show the antimicrobial susceptibility pro-
files of various Gram-positive and Gram-negative patho-
gens isolated from ICU patients against a range of relevant
antimicrobials.
Specifically notable susceptibility patterns include the
vancomycin susceptibility of all strains of staphylococci.
Generally, there was a low proportion of vancomycin
resistant E. faecalis <5%, whereas vancomycin-resistant E.
faecium was more prevalent ranging from 0.8% in France
to 76.3% in the United States, with a wide inter-country
variation (Table 2). Penicillin resistance rates varied
among S. pneumoniae, from 2.0% in Germany to 20.2% in
the US with concurrent ceftriaxone resistance rates of 0%
in Germany to 3.4% in Italy (Table 3).
β-lactam activity was assessed by comparing four different
cephalosporins and a β-lactam/β-lactamase inhibitor
combination, piperacillin-tazobactam. Overall, the puta-
tive production of ESBLs among E. coli was low, <6%, but
ceftazidime resistance was reported at higher rates in K.
pneumoniae and S. marcescens, with the highest rates seen
in M. morganii, from 16.0% in Germany to 26.4% in the
United States (Table 4). Among the gram-negative organ-
isms tested, ceftriaxone resistance rates were usually lower
than ceftazidime, with the exception among P. aeruginosa
and  Acinetobacter spp. Cefepime, a fourth generation
cephalosporin with anti-pseudomonal activity was also
more active than ceftazidime (Table 5). Against the Entero-
bacteriaceae, the β-lactam combination agent piperacillin-
tazobactam was generally less active than ceftriaxone.
These species showed a wide variation in fluoroquinolone
susceptibility among both species and countries. Gen-
tamicin resistance rates among the Enterobacteriaceae var-
ied from 1.2% among K. oxytoca from Germany to 37.2%
in P. mirabilis from Italy. Ciprofloxacin resistance rates
among E. coli ranged from 6.5% in France to 12.7% in
Table 1: Incidence of pathogens isolated from ICU patients by country (%)
United States Canada Italy Germany France
Organism Incidence (%) Organism Incidence (%) Organism Incidence (%) Organism Incidence (%) Organism Incidence (%)
S. aureusa 20.2 S. aureusa 17.4 P. aeruginosa 22.3 CNS 16.4 S. aureus1 17.2
CNSb 15.9 CNS 16.1 CNS 18.7 S. aureusa 13.6 CNS 16.7
P. aeruginosa 13.1 E. coli 12.6 S. aureusa 18.1 E. coli 12.3 E. coli 15.5
E. coli 9.2 P. aeruginosa 11.3 E. coli 7.7 P. aeruginosa 10.8 P. aeruginosa 13.8
K. pneumoniae 5.8 Enterococcus spp 7.6 E. faecalis 3.9 Enterococcus spp 7.4 S. pneumoniae 3.3
Enterococcus spp 5.4 K. pneumoniae 5.5 K. pneumoniae 3.5 K. pneumoniae 5.4 E. cloacae 3.3
E. cloacae 4.3 E. cloacae 4.2 Enterococcus spp 3.3 E. cloacae 4.7 E. faecalis 3.0
E. faecalis 3.7 S. marcenscens 2.5 E. cloacae 2.6 E. faecalis 4.3 K. pneumoniae 2.7
S. marcescens 2.7 H. influenzae 2.1 S. marcescens 2.2 P. mirabilis 2.6 P. mirabilis 2.5
A. baumanii 2.6 E. faecalis 2.1 P. mirabilis 1.9 K. oxytoca 2.4 Enterococcus spp 2.3
Enterobacteriaceaec 
(all species 
combined)
29.5 Enterobacteriaceae 
(all species 
combined)
33.0 Enterobacteriaceae 
(all species 
combined)
30.2 Enterobacteriaceae 
(all species 
combined)
36.0 Enterobacteriaceae 
(all species 
combined)
32.1
Total (n) 26,624 Total (n) 54,445 Total (n) 34,609 Total (n) 48,385 Total (n) 62,459
aProportion of S. aureus testing as MRSA was USA (52.3%), Canada (19.7%), Italy (59.4%), Germany (21.0%), and France (40.6%) bCNS = Coagulase-negative staphylococci 
cEnterobacteriaceae includes all species of genera occurring at >0.1%Annals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
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Table 2: S. aureus, Coagulase-negative staphylococci, E. faecalis, and E. faecium isolated from ICU patients during 2000–2002
United States Canada Italy Germany Francea
Organism Agent Total n %S %R Total n %S %R Total n %S %R Total n %S %R Total n %S %R
Staphylococcus 
aureus
Ampicillin 19,703 6.7 93.3 3,792 12.6 87.4 1,665 5.6 94.4 2,867 16.2 83.8 15 6.7 93.3
Cefepime 1,260 52.9 46.9 NTb NT NT 304 15.8 84.2 483 80.5 17.0 <10 NAc> NA
Cefotaxime 6,898 50.2 49.7 220 55.5 44.5 671 36.4 63.6 729 92.0 8.0 490 63.9 36.1
Ceftriaxone 5,914 45.6 54.3 153 69.3 30.7 1,048 28.1 71.8 220 88.6 11.4 23 73.9 26.1
Ciprofloxacin 24,350 47.4 51.0 5,958 74.5 24.1 4,600 39.7 58.6 5,243 73.4 26.1 316 57.0 40.5
Gentamicin 35,034 85.6 13.7 6,641 89.4 10.3 5,531 40.9 58.0 5,735 90.0 9.7 10,100 90.4 9.4
Oxacillin 44,939 47.7 52.3 10,105 80.3 19.7 6,147 40.6 59.4 6,475 79.0 21.0 10,512 59.4 40.6
Teicoplanin NT NT NT NT NT NT 5,868 100 0 4,632 99.8 0.2 8,232 100 0
Vancomycin 43,245 100 0 7,882 100 0 5,937 100 0 5,276 100 0 9,453 100 0
Staphylococcus 
aureus
OSSA Ampicillin 9,047 14.5 85.5 3,055 15.7 84.3 741 12.6 87.4 2,414 19.3 80.7 10 0 100
Cefepime 672 99.1 0.4 NT NT NT 49 98.0 2.0 387 99.5 0.3 NT NT NT
Cefotaxime 3,451 99.7 0.2 122 100 0 244 100 0 653 100 0 312 100 0
Ceftriaxone 2,707 99.5 0.2 106 100 0 295 99.0 0.3 194 100 0 16 100 0
Ciprofloxacin 11,827 91.2 6.5 4,692 93.5 4.8 1,902 91.4 4.9 4,171 91.4 8.0 188 90.4 6.4
Gentamicin 16,951 98.3 1.4 5,384 98.1 1.8 2,223 95.1 4.5 4,527 98.4 1.5 5,958 99.4 0.5
Oxacillin 21,416 100 0 8,110 100 0 2,495 100 0 5,115 100 0 6,244 100 0
Teicoplanin NT NT NT NT NT NT 2,402 100 0 3,593 99.9 0.1 5,018 100 0
Vancomycin 20,110 100 0 6,046 100 0 2,430 100 0 4,002 100 0 5,580 100 0
Staphylococcus 
aureus
ORSA Ampicillin 10,656 0 100 737 0 100 924 0 100 453 0 100 <10 NA NA
Cefepime 588 0 100 NT NT NT 255 0 100 96 4.2 84.4 <10 NA NA
Cefotaxime 3,447 0.6 99.3 98 0 100 427 0 100 76 23.7 76.3 178 0.6 99.4
Ceftriaxone 3,207 0 100 47 0 100 753 0.3 99.7 26 3.8 96.2 <10 NA NA
Ciprofloxacin 12,523 6.1 93.1 1,266 3.9 95.5 2,698 3.3 96.4 1,072 3.3 96.6 128 7.8 90.6
Gentamicin 18,083 73.7 25.2 1,257 52.0 46.8 3,308 4.5 94.0 1,208 58.7 40.5 4,142 77.5 22.2
Oxacillin 23,523 0 100 1,995 0.2 99.8 3,652 0 100 1,360 0 100 4,268 0 100
Teicoplanin NT NT NT NT NT NT 3,466 100 0 1,039 99.7 0.3 3,214 100 0
Vancomycin 23,135 100 0 1,836 100 0 3,507 100 0 1,274 100 0 3,873 100 0
Staphylcoccus 
species, coagulase-
negative
Ampicillin 16,288 5.7 94.3 3,533 6.3 93.7 2,142 10.6 89.4 4,075 8.1 91.9 <10 NA NA
Cefepime 991 11.8 88.1 <10 NA NA 116 0 100 625 11.0 73.1 <10 NA NA
Cefotaxime 5,538 17.7 82.3 240 17.9 82.1 335 16.7 83.3 625 37.4 62.4 174 28.7 69.0
Ceftriaxone 3,471 14.8 84.8 116 22.4 77.6 512 11.7 88.3 412 25.0 74.8 <10 NA NA
Ciprofloxacin 18,829 40.2 58.3 5,366 44.4 54.7 5,102 42.7 54.0 6,197 29.5 67.6 198 44.4 53.0
Gentamicin 27,248 51.5 38.1 5,571 40.6 47.3 5,241 33.8 60.7 6,848 41.5 51.7 9,422 46.8 51.5
Oxacillin 35,135 15.8 84.2 9,172 20.6 79.4 5,961 15.2 84.8 7,442 18.6 81.4 9,884 30.1 69.9
Teicoplanin NT NT NT NT NT NT 5,797 93.7 2.4 5,096 95.6 0.7 7,670 84.6 3.1
Vancomycin 34,424 100 0 8,239 100 0 5,937 100 0 6,953 100 0 8,300 100 0
Staphylcoccus 
species, coagulase-
negative
Oxacillin 
susceptible
Ampicillin 2,582 35.7 64.3 638 34.6 65.4 437 51.7 48.3 824 39.6 60.4 <10 NA NA
Cefepime 117 100 0 NT NT NT NT NT NT <10 NA NA NT NT NT
Cefotaxime 978 99.5 0.2 42 100 0 56 100 0 128 100 0 54 92.6 0
Ceftriaxone 523 98.3 0.4 26 100 0 59 100 0 103 100 0 <10 NA NA
Ciprofloxacin 2,844 82.4 16.6 988 91.8 7.6 779 87.7 10.1 1,103 89.5 9.2 78 83.3 14.1
Gentamicin 4,424 93.5 4.2 1,068 91.9 5.3 698 94.3 5.3 1,263 96.5 2.7 2,822 93.9 5.4
Oxacillin 5,565 100 0 1,886 99.9 0.1 904 100 0 1,383 100 0 2,980 100 0
Teicoplanin NT NT NT NT NT NT 890 99.1 0.3 691 98.4 0.3 2,454 95.8 0.2
Vancomycin 5,240 100 0 1,587 100 0 897 100 0 981 100 0 2,467 100 0
Staphylcoccus 
species, coagulase-
negative
Oxacillin resistant Ampicillin 13,706 0.1 99.9 2,895 0 100 1,705 0 100 3,251 0.2 99.8 <10 NA NA
Cefepime 874 0 99.9 <10 NA NA 116 0 100 624 10.9 73.2 <10 NA NAAnnals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
Page 5 of 11
(page number not for citation purposes)
Italy. Variable fluoroquinolone resistance rates among S.
marcescens were also demonstrated, with a range of resist-
ance from 4.5% in Italy to 12.4% in Germany.
Discussion
Data derived from international surveillance studies, such
as those presented here, can provide a unique contempo-
rary perspective on the susceptibility of commonly
encountered organisms to commonly used antibiotics.
Such surveillance systems play a crucial role in detecting
emerging trends in resistance. Comparisons of these with
data of other recent surveillance programs show the wide
variations in susceptibility profiles and the need for ongo-
ing unit-specific surveys.
In Germany the prevalence of resistance among gram-pos-
itive organisms remained comparatively low with an inci-
dence of 21% MRSA. In 2000, Frank et al. reported that
96% of German isolates of S. marcescens and M. morganii
were susceptible to ceftazidime, yet in this study we found
89.7% and 84.0%, respectively [9]. A similar decrease in
activity was noted with E. coli and ciprofloxacin between
the two studies, 91% in 1996–1997 compared with
86.7% in this study. Marked decreases in susceptibility of
P. aeruginosa in Germany were also evident, with no agent
showing >85.8% susceptibility (piperacillin-tazobactam)
compared with most agents having 85%–94% susceptibil-
ity in 1996–1997. Changes of 15–20% have been
reported with ceftazidime, imipenem, ciprofloxacin and
meropenem, while piperacillin-tazobactam has shown
the smallest decrease in susceptibility with <6% over the
4-year period. Piperacillin plus or minus tazobactam and
cefepime were the most active agents, based on suscepti-
bility, against P. aeruginosa in Germany. Conversely, ceftri-
axone and imipenem were the most active agents, based
on susceptibility, against Klebsiella spp., which account for
almost 8% of ICU isolates.
Staphylococcal species from French ICU isolates showed a
high proportion of oxacillin resistance, 40.6% and 69. 9%
of  S. aureus and coagulase-negative staphylococci spp.,
respectively. S. pneumoniae showed penicillin resistance of
17.9%, higher than the other four countries, although the
activity of third-generation cephalosporins, ceftriaxone
and cefotaxime, showed only 0.6% and 0.8% resistance,
respectively. Despite a lower ceftazidime susceptibility
breakpoint compared to NCCLS standards (MIC 4 µg/ml
instead of 8 µg/ml) putative ESBL expression were slightly
lower in France than in Germany in 2000–2002. Ceftazi-
dime non-susceptibility rates among E. coli, K. oxytoca,
and P. mirabilis were ≤ 2.2%; however, ceftazidime non-
susceptibility rates among K. pneumoniae, M. morganii and
S. marcescens were 7.5%, 21.4%, and 5.3%, respectively.
Imipenem was active against all Enterobacteriaceae. Against
P. aeruginosa and Acinetobacter spp., imipenem resistance
rates were 21.4% and 3.8%, respectively. Previously, a
lower imipenem resistance of 24% among French isolates
of P. aeruginosa was reported [7].
Among the Italian isolates of staphylococci, oxacillin
resistance occurred in 59.4% of S. aureus and 84.8% of
coagulase-negative isolates. This MRSA rate was similar to
that reported by Frank et al. from bacteremic isolates in
Italy; however, they reported an increase in MRSA from
Cefotaxime 4,560 0.1 99.9 198 0.5 99.5 279 0 100 497 21.3 78.5 120 0 100
Ceftriaxone 2,948 0 99.8 90 0 100 453 0.2 99.8 309 0.0 99.7 <10 NA NA
Ciprofloxacin 15,985 32.7 65.8 4,378 33.7 65.3 4,323 34.7 61.9 5,094 16.5 80.2 120 19.2 78.3
Gentamicin 22,824 43.3 44.7 4,503 28.5 57.3 4,543 24.5 69.2 5,585 29.1 62.8 6,600 26.6 71.3
Oxacillin 29,570 0 100 7,286 0 100 5,057 0 100 6,059 0 100 6,904 0 100
Teicoplanin NT NT NT NT NT NT 4,907 92.7 2.8 4,405 95.1 0.8 5,216 79.3 4.5
Vancomycin 29,184 100 0 6,652 100 0 5,040 100 0 5,972 100 0 5,833 100 0
Enterococcus faecalis
Ampicillin 7,865 98.8 1.2 1,000 99.4 0.6 1,289 95.3 4.7 1,902 99.6 0.4 1,183 99.5 0.2
Ciprofloxacin 3,311 56.9 38.7 625 45.3 50.4 1,159 64.0 31.1 2,012 39.7 39.5 559 78.5 17.0
Gentamicin 
(HL Testing)
5,503 65.1 34.8 706 63.0 36.8 1,156 62.9 37.1 965 64.8 35.2 1,563 63.6 13.4
Teicoplanin NT NT NT <10 NA NA 1,248 97.1 2.4 1,294 99.7 0.2 1,747 99.9 0.1
Vancomycin 7,656 95.1 4.5 1,005 98.3 0.9 1,303 96.7 2.8 1,636 99.4 0.3 1,811 99.7 0.2
Enterococcus faecium
Ampicillin 3,896 9.7 90.3 383 17.2 82.8 260 21.5 78.5 481 12.3 87.7 151 41.7 49.7
Ciprofloxacin 1,846 5.3 92.5 221 10.9 85.5 234 10.3 77.4 591 6.9 73.9 66 21.2 39.4
Gentamicin 
(HL Testing)
2,512 57.5 42.5 291 59.5 40.5 223 67.7 32.3 349 60.2 39.8 263 65.4 12.2
Teicoplanin 23 8.7 87.0 <10 NA NA 234 86.3 13.7 517 97.9 2.1 266 99.6 0.4
Vancomycin 4,066 23.2 76.3 415 85.1 14.5 264 75.4 24.2 628 93.9 4.8 247 98.4 0.8
aNCCLS breakpoints were used for all countries, except (CA-SFM) bNot tested cNot applicable if <10 isolates were tested
Table 2: S. aureus, Coagulase-negative staphylococci, E. faecalis, and E. faecium isolated from ICU patients during 2000–2002 (Continued)Annals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
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25% to 55% over the period 1997 to 2001 [18]. Vancomy-
cin resistance rates of 2.8% for E. faecalis and 24.2% for E.
faecium are some of the highest rates recorded in Europe,
although still modest compared to rates experienced in
the United States; however, teicoplanin was more active
with 2.4% and 13.7% of strains being resistant, respec-
tively. Pneumococcal resistance to penicillin and erythro-
mycin was 7.6% and 28.1%, respectively. The impact of
alterations in penicillin-binding protein that reduce peni-
cillin susceptibility have less effect on the activity of third-
generation cephalosporins such as ceftriaxone with 3.4%
and cefotaxime with 4.6% resistance, respectively. S. pyo-
genes was fully susceptible to penicillin; however, 11.8%
of isolates were resistant to clarithromycin and 23.7%
were resistant to erythromycin.
The proportion of ESBLs was slightly higher in Italy with
E. coli showing ceftazidime non-susceptibility of 5.3%,
Table 3: S. pneumoniae, S. pyogenes, S. agalactiae, and Viridans group streptococci isolated from ICU patients during 2000–2002
United States Canada Italy Germany Francea
Organism Agent Total n %S %R Total n %S %R Total n %S %R Total n %S %R Total n %S %R
Streptococcus 
pneumoniae
Amoxicillin 120 91.7 2.5 31 100 0 60 93.3 6.7 17 100 0 1,328 71.2 2.3
Cefepime 22 90.9 4.5 25 60.0 12.0 66 90.9 7.6 NTb NT NT <10 NAc NA
Cefotaxime 1,571 82.2 6.3 145 93.8 0.7 108 93.5 4.6 63 100 0 1,181 77.1 0.8
Ceftriaxone 2,373 88.3 3.2 145 91.7 0.7 145 91.7 3.4 29 100 0 544 80.1 0.6
Clarithromycin 184 71.7 25.5 56 69.6 30.4 90 64.4 31.1 <10 NA NA NT NT NT
Erythromycin 3,029 67.9 30.5 539 78.5 20.8 313 69.6 28.1 405 88.6 9.4 1,567 59.0 38.8
Levofloxacin 2,133 99.1 0.4 356 98.6 1.1 174 98.3 0.6 340 99.4 0.3 62 98.4 1.6
Penicillin 3,096 51.5 20.2 325 59.1 7.1 198 77.3 7.6 102 96.1 2.0 1,387 45.5 17.9
Vancomycin 2,865 100 -c 271 100 - 231 100 - 190 100 - 1,479 100 -
Streptococcus 
pyogenes
Amoxicillin NT NT NT NT NT NT NT NT NT NT NT NT 58 100 0
C e f e p i m e < 1 0 N AN A N T N TN T N T N TN T N T N TN T N T N TN T
Cefotaxime 32 100 - 29 100 - <10 NA NA 11 100 - 30 100 -
Ceftriaxone 75 100 - <10 NA NA <10 NA NA <10 NA NA <10 NA NA
Clarithromycin 19 84.2 5.3 <10 NA NA 17 88.2 11.8 NT NT NT NT NT NT
Erythromycin 118 92.4 6.8 102 81.4 11.8 59 74.6 23.7 63 84.1 11.1 170 82.9 14.7
Levofloxacin 71 97.2 1.4 <10 NA NA <10 NA NA 61 77.0 4.9 NT NT NT
Penicillin 140 100 - 97 100 - 58 100 - 64 100 - 139 100 -
Vancomycin 121 100 - 42 100 - 12 100 - 34 100 - 162 100 -
Streptococcus 
agalactiae
Amoxicillin NT NT NT NT NT NT NT NT NT NT NT NT 165 100 0
Cefepime 28 100 - NT NT NT <10 NA NA NT NT NT NT NT NT
Cefotaxime 71 100 - 17 100 - 24 100 - 50 100 - 50 100 -
Ceftriaxone 184 100 - <10 NA NA 38 100 - 37 100 - <10 NA NA
Clarithromycin 21 81.0 9.5 <10 NA NA 21 71.4 28.6 NT NT NT <10 NA NA
Erythromycin 489 76.3 21.7 222 82.9 14.9 121 77.7 18.2 192 83.9 10.9 588 79.9 16.2
Levofloxacin 333 97.9 1.2 <10 NA NA 51 98.0 0 180 91.1 1.7 173 99.4 0
Penicillin 518 100 - 226 100 - 145 100 - 184 100 - 369 100 -
Vancomycin 463 100 - 179 100 - 143 100 - 65 100 - 526 100 -
Streptococcus 
viridans group
Amoxicillin NT NT NT NT NT NT NT NT NT NT NT NT 268 92.9 0.7
Cefepime 23 95.7 4.3 NT NT NT 12 66.7 33.3 NT NT NT NT NT NT
Cefotaxime 434 83.6 11.1 101 92.1 4.0 31 90.3 9.7 75 97.3 2.7 56 94.6 0
Ceftriaxone 678 87.3 7.7 130 89.2 3.8 99 81.8 18.2 40 97.5 2.5 <10 NA NA
Clarithromycin 34 52.9 38.2 21 76.2 19.0 21 71.4 23.8 <10 NA NA NT NT NT
Erythromycin 959 57.2 37.7 289 71.6 23.2 192 64.6 32.8 796 88.1 9.2 626 59.9 31.6
Levofloxacin 331 96.1 2.7 <10 NA NA 16 87.5 0 93 89.2 4.3 <10 NA NA
Penicillin 1,047 63.7 6.2 303 79.2 0 61 78.7 8.2 <10 NA NA 452 69.0 3.1
Vancomycin 1,095 100 - 276 100 - 180 100 - 277 100 - 580 100 -
aNCCLS breakpoints were used for all countries, except France (CA-SFM) bNot tested cBreakpoints do not currently exist to interpret as S (susceptible) or 
R (resistant)Annals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
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Table 4: Enterobacteriaceae isolated from ICU patients during 2000–2002
United States Canada Italy Germany Francea
Organism Agent Total n %S %R Total n %S %R Total n %S %R Total n %S %R Total n %S %R
Escherichia coli Cefepime 10,356 98.1 1.5 207 98.1 1.9 1,426 98.1 1.4 2,830 98.6 1.2 4,358 98.9 0.6
Cefotaxime 9,086 96.5 2.2 3,231 96.3 2.5 1,748 94.5 3.8 5,828 97.8 1.8 9,362 98.8 0.6
Ceftazidime 14,574 95.3 3.0 4,438 97.7 1.6 2,548 94.7 3.7 3,924 97.9 1.6 9,164 97.8 1.2
Ceftriaxone 15,897 97.4 1.7 3,829 96.8 2.2 1,423 94.4 4.2 534 99.8 0.2 834 98.6 1.0
Ciprofloxacin 17,294 89.0 10.7 5,028 90.3 9.5 2,616 87.0 12.7 4,615 86.7 12.4 8,577 93.1 6.5
Gentamicin 20,581 92.4 6.5 6,654 92.8 5.3 2,650 92.2 6.6 4,825 94.3 5.2 9,442 95.4 4.2
Imipenem 15,353 100 0 3,386 100 0 2,254 100 0 5,172 100 0 8,994 100 0
Levofloxacin 14,920 88.2 11.6 776 85.1 13.9 496 86.5 13.3 3,137 88.2 11.0 NTb NT NT
Piperacillin-
tazobactam
13,573 93.1 3.6 4,305 95.1 2.4 1,879 95.8 2.4 5,637 93.6 3.4 7,255 95.4 1.1
Trimethoprim-
sulfamethoxazole
20,296 79.2 20.7 6,737 84.6 15.3 2,440 75.0 24.9 5,598 73.1 26.6 9,028 78.2 21.1
Klebsiella oxytoca
Cefepime 1,476 96.2 3.3 19 100 0 255 99.6 0 566 96.8 2.7 478 97.1 0.4
Cefotaxime 1,324 92.7 4.7 486 94.2 4.5 230 96.5 1.7 1,117 93.8 4.4 865 96.3 0.8
Ceftazidime 1,909 91.7 7.0 661 94.9 4.1 361 83.4 15.2 749 95.3 4.5 870 98.3 0.5
Ceftriaxone 2,035 89.9 6.6 536 93.8 2.8 197 81.7 2.0 83 97.6 0 79 87.3 2.5
Ciprofloxacin 2,226 92.5 5.9 745 96.0 3.0 368 96.7 3.0 905 90.1 7.8 815 94.5 4.8
Gentamicin 2,569 89.9 8.3 857 95.0 4.9 366 89.6 3.0 1,016 98.2 1.2 865 97.1 2.4
Imipenem 2,061 100 0 516 100 0 337 100 0 1,062 100 0 845 100 0
Levofloxacin 1,754 93.3 3.4 159 96.9 1.3 133 97.0 3.0 560 94.6 3.2 NT NT NT
Piperacillin-
tazobactam
1,801 82.7 13.9 624 91.2 7.1 313 81.8 11.2 1,113 78.9 18.1 742 88.3 10.4
Trimethoprim-
sulfamethoxazole
2,467 92.5 7.5 863 96.3 3.6 308 95.1 4.9 1,084 93.7 6.3 802 94.1 5.7
Klebsiella 
pneumoniae
Cefepime 7,276 95.8 3.4 98 100 0 552 93.5 5.6 1,068 95.7 3.5 840 95.6 3.0
Cefotaxime 6,243 91.0 6.1 1,411 97.9 1.5 850 76.7 16.4 2,414 93.1 6.0 1,553 94.4 1.9
Ceftazidime 9,597 88.5 10.1 2,238 97.5 2.2 1,142 69.8 28.5 1,665 90.0 8.2 1,591 92.5 5.2
Ceftriaxone 10,337 92.7 4.7 1,736 97.9 1.1 816 75.2 15.0 166 98.8 0.6 112 86.6 5.4
Ciprofloxacin 11,089 89.9 8.4 2,484 91.8 7.2 1,190 88.2 9.9 2,128 85.4 9.4 1,473 89.5 8.7
Gentamicin 13,012 91.6 7.0 2,906 96.7 2.9 1,211 81.4 14.5 2,065 91.6 6.1 1,553 97.1 2.7
Imipenem 10,263 100 0 1,766 100 0 1,066 100 0 2,351 100 0 1,567 100 0
Levofloxacin 9,626 91.0 6.4 485 93.4 3.7 287 78.4 21.3 1,228 92.6 4.4 NT NT NT
Piperacillin-
tazobactam
9,359 85.9 7.4 2,160 91.5 2.7 746 82.2 14.6 2,408 84.9 8.3 1,286 89.4 5.1
Trimethoprim-
sulfamethoxazole
12,641 88.6 11.1 2,924 92.8 7.1 1,103 82.0 18.0 2,324 82.2 17.2 1,443 88.2 10.9
Morganella 
morganii
Cefepime 566 95.9 2.3 <10 NA NA 121 97.5 2.5 262 94.7 5.0 412 96.1 0.2
Cefotaxime 499 78.8 8.4 156 91.0 3.8 144 74.3 6.3 437 86.7 3.9 678 81.1 5.9
Ceftazidime 715 73.6 17.3 256 79.7 10.9 213 75.6 15.0 313 84.0 7.7 673 78.6 8.0
Ceftriaxone 806 91.1 2.2 219 96.3 1.4 125 91.2 3.2 22 86.4 0 57 84.2 5.3
Ciprofloxacin 841 78.1 20.7 292 94.2 4.5 220 87.3 9.5 344 97.7 2.0 634 88.6 8.5
Gentamicin 967 84.0 14.1 329 94.5 4.6 222 90.1 8.6 378 96.8 2.1 679 95.6 3.4
Imipenem 784 100 0 196 100 0 206 100 0 402 100 0 649 99.8 0
Levofloxacin 725 78.1 19.3 42 95.2 4.8 55 90.9 9.1 251 98.0 1.6 NT NT NT
Piperacillin-
tazobactam
725 91.2 5.1 254 97.2 1.6 150 94.0 3.3 430 94.2 3.5 564 91.0 4.6
Trimethoprim-
sulfamethoxazole
936 75.1 24.7 329 91.8 8.2 193 79.8 20.2 435 93.1 6.9 627 83.9 14.2
Proteus mirabilis
Cefepime 1,964 98.2 1.0 20 100 0 395 87.6 11.4 599 99.2 0.8 736 99.0 0.1
Cefotaxime 1,794 99.1 0.5 295 99.7 0 441 69.4 23.4 1,209 98.8 0.7 1,503 99.5 0.1
Ceftazidime 2,684 98.0 1.1 463 99.4 0.2 630 86.0 9.4 821 98.5 1.0 1,505 99.3 0.2
Ceftriaxone 3,034 99.4 0.3 392 99.5 0 385 80.5 13.8 77 98.7 0 72 100 0
Ciprofloxacin 3,169 85.2 12.7 504 95.2 4.6 657 70.6 22.7 980 92.9 5.1 1,424 90.9 6.8
Gentamicin 3,796 91.5 7.7 698 92.6 7.2 670 61.6 37.2 992 92.9 5.9 1,509 91.3 7.9
Imipenem 2,850 100 0 367 100 0 580 100 0 1,020 100 0 1,319 100 0
Levofloxacin 2,825 87.8 10.5 94 100 0 202 61.9 34.7 688 96.5 2.3 <10 NAc NAAnnals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
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whereas  K. pneumoniae and K. oxytoca demonstrated
30.2% and 16.6% ceftazidime non-susceptibility, respec-
tively. Fluoroquinolone resistance rates among the Entero-
bacteriaceae, using ciprofloxacin as a marker, varied from
3.0% for K. oxytoca to 22.7% for P. mirabilis, and 12.7% for
E. coli. Thus, among Enterobacteriaceae, ciprofloxacin was
generally less active than the third-generation
cephalosporin, ceftriaxone. P. aeruginosa and Acinetobacter
spp. strains from Italian ICUs demonstrated significant
resistance rates. Isolates of P. aeruginosa showed resistance
rates of >28% for all agents tested except piperacillin-tazo-
bactam. Thus empiric therapy for possible pseudomonal
infections will require combination therapy. Acinetobacter
spp. showed a similar lack of susceptibility except to imi-
penem and meropenem (19.0% and 13.6% resistant). An
increase in fluoroquinolone resistance in E. coli and K.
pneumoniae in bacteremic isolates from Italy was observed
during 1997–2001, with rates of 26.7% and 24%, respec-
tively [9]. An increase in ureidopenicillin resistance was
noted in P. aeruginosa isolates in Italy from 30% to 37% in
a 4-year period [9]. This study showed 22.0% piperacillin-
tazobactam and 36.7% piperacillin resistance among ICU
P. aeruginosa isolates.
In Canada oxacillin-resistance among S. aureus was noted
in 19.7% and coagulase-negative staphylococci in 79.4%.
Vancomycin resistance was reported among 0.9% and
14.5% of E. faecalis and E. faecium, respectively. The low-
est rate of penicillin resistance in S. pneumoniae in this
study was noted from Canada at 7.1%; however, clarithro-
mycin resistance was 30.4%. Ceftriaxone showed 0.7%
resistance whereas cefepime exhibited 12.0% resistance
among pneumococci from the ICU.
Overall the susceptibility rates for Gram-negative isolates
from Canadian ICUs were higher than those in the other
four countries examined. A low rate of ESBLs was
reported, but there was variable activity of piperacillin-
tazobactam which showed >9% resistance among Kleb-
siella spp. and S. marcescens tested. The rate of fluoroqui-
nolone resistance was similar to those of other countries
with  E. coli showing 13.9% levofloxacin resistance.
Among  Enterobacteriaceae, <10% of most species were
resistant to third-generation cephalosporins tested with
the exception of ceftazidime and M. morganii. Resistance
among P. aeruginosa and Acinetobacter spp. was generally
lower than in other countries apart from Germany. Only
piperacillin-tazobactam showed reliable activity against P.
aeruginosa (9% resistant), while resistance to all other
agents was >19%. Acinetobacter spp. remained susceptible
to only the carbapenems, imipenem and meropenem.
Comparison of the data from Canadian isolates with
those from the United States shows some significant dif-
ferences. This demonstrates the limitations of pooling
Canadian and United States data since the differences
between the two regions, such as the rate of MRSA, may
have some impact on empiric therapy. Data from the
NNIS system has previously reported an increasing trend
towards resistance within ICUs in the United States [19].
Oxacillin resistance among staphylococci from ICUs in
the United States was 52.3% and 84.2% for S. aureus and
coagulase-negative species, respectively.
This value is identical to that of S. aureus and very similar
to the CNS data reported by the 1999 NNIS system. The
NNIS highlighted a 37% increase in MRSA over the period
Piperacillin-
tazobactam
2,715 97.7 0.8 449 98.2 0.2 465 95.7 2.8 1,201 98.6 0.8 1,231 99.3 0.2
Trimethoprim-
sulfamethoxazole
3,706 85.2 14.7 708 89.4 10.6 615 61.6 38.0 1,159 80.8 19.1 1,411 79.7 18.6
Serratia 
marcescens
Cefepime 3,653 96.7 2.3 52 96.2 1.9 497 96.8 2.2 546 94.1 3.5 509 98.6 0.2
Cefotaxime 3,134 87.0 5.7 670 92.8 2.7 470 79.6 9.8 951 84.0 7.5 809 81.5 3.3
Ceftazidime 4,718 89.7 7.9 1,113 95.2 3.0 738 81.4 13.3 851 89.7 7.5 812 94.7 3.0
Ceftriaxone 4,710 90.5 4.6 846 95.4 1.7 444 86.7 6.3 160 45.6 0 115 77.4 4.3
Ciprofloxacin 5,006 91.0 6.7 1,292 85.0 11.7 757 83.5 4.5 978 72.6 12.4 787 78.9 10.5
Gentamicin 5,905 92.9 5.9 1,313 94.6 5.2 758 97.4 2.1 665 92.9 6.3 808 91.6 6.6
Imipenem 4,960 100 0 880 100 0 727 100 0 1,018 100 0 805 100 0
Levofloxacin 4,356 94.3 4.2 264 92.4 4.2 266 95.5 1.5 595 87.6 6.6 <10 NA NA
Piperacillin-
tazobactam
4,337 88.1 5.1 1,155 91.6 3.3 547 92.7 3.8 1,053 77.6 3.1 749 82.6 2.4
Trimethoprim-
sulfamethoxazole
5,697 95.9 3.9 1,325 94.9 5.1 646 81.4 18.6 908 88.1 10.9 699 84.1 13.6
aNCCLS breakpoints were used for all countries, except France (CA-SFM) bNot tested cNot applicable if <10 isolates were tested
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1994–98 to 1999, but only a 2% increase among CNS
strains [4]. Vancomycin resistance in the United States
was observed in 4.5% of E. faecalis; however, over 76% E.
faecium were vancomycin non-susceptible.
Although streptococci are uncommon ICU pathogens
they can be rapidly invasive and possibly fatal unless ade-
quate therapeutic approaches are adopted. S. pneumoniae
in the United States has acquired a range of resistance
mechanisms with resistance to penicillin and the mac-
rolides, clarithromycin and erythromycin, being com-
mon, 20.2% and 25.5%–30.5% respectively. The newer
generation cephalosporins, ceftriaxone, cefotaxime and
cefepime showed good activity against pneumococci,
3.2%, 6.3% and 4.5% resistant, respectively. Less than
1.0% of isolates were resistant to levofloxacin. These data
are similar to other recent reports [20].
For  Enterobacteriaceae which account for approximately
30% of all isolates from ICU infections, the incidence of
putative ESBLs was low in E. coli, 4.7% but ceftazidime
non-susceptibility was higher in K. oxytoca 8.3%,K. pneu-
moniae 11.5%,S. marcescens 10.3% and M. morganii
26.4%. These data are consistent with other recent reports
[21]. Fluoroquinolone resistance was observed in all
Enterobacteriaceae tested, in the US for example, resistance
rates were as follows, using ciprofloxacin as a marker: E.
coli 10.7%, K. oxytoca 5.9%, K. pneumoniae 8.4%, M. mor-
ganii 20.7%, P. mirabilis 12.7% and S. marcescens 6.7%.
These data show increased fluoroquinolone resistance
compared with recent reports [21]. Jones et al. previously
reported susceptibility data on ICU pathogens isolated
over the period 1998–2001 [22].
Specifically, enteric bacteria showed changes over this
time. Fluoroquinolone resistance doubled among E. coli
isolates from 3.3–5.5% to 10.8–11.4% [22]. This study
showed a generally higher level of activity among third-
generation cephalosporins than other reports [23], with
ceftriaxone showing <10% resistance rates against most
species tested. Piperacillin-tazobactam showed less con-
sistent activity with some species being >14% resistant,
Table 5: P. aeruginosa and Acinetobacter spp isolated from ICU patients during 2000–2002
United States Canada Italy Germany France
Organism Agent Total n %S %R Total n %S %R Total n %S %R Total n %S %R Total n %S %R
Acinetobacter 
species
Cefepime 5,162 43.8 40.2 97 67.0 23.7 475 17.9 73.7 623 74.2 10.8 857 28.0 40.3
Cefotaxime 3,830 23.3 49.9 705 36.7 34.9 555 11.0 78.7 1,254 34.9 24.6 671 15.4 38.7
Ceftazidime 5,954 42.2 40.8 1,162 70.8 22.9 692 25.6 68.5 988 66.7 14.5 1,106 34.9 35.5
Ceftriaxone 4,709 16.3 55.9 874 32.4 28.7 452 8.8 72.6 104 42.3 11.5 81 9.9 51.9
Ciprofloxacin 5,808 39.7 58.0 1,156 72.1 25.9 686 21.1 76.7 1,126 74.8 22.9 1,038 37.7 61.2
Gentamicin 6,618 47.2 47.2 1,185 72.8 22.8 768 23.3 72.4 979 82.0 14.1 936 49.3 43.5
Imipenem 6,006 87.0 7.5 918 95.8 1.9 569 77.9 19.0 1,253 96.2 3.4 1,088 93.8 3.8
Levofloxacin 5,099 43.8 52.2 489 61.1 25.6 295 13.9 75.3 840 82.0 10.5 NTb NT NT
Meropenem 2,154 66.3 26.5 348 93.7 4.9 455 74.5 13.6 1,024 96.0 3.4 147 68.0 28.6
Piperacillin 4,658 35.4 45.9 959 66.5 19.5 635 19.5 69.9 1,171 59.7 12.9 805 35.0 50.3
Piperacillin-
tazobactam
3,429 53.6 28.5 903 70.7 23.1 425 35.1 46.4 1,225 81.8 7.5 878 74.5 10.5
Trimethoprim-
sulfamethoxazole
5,697 51.4 48.4 1,155 74.8 25.2 750 44.1 55.7 1,234 83.6 15.6 93 45.2 52.7
Pseudomonas 
aeruginosa
Cefepime 20,220 72.5 12.4 371 73.3 12.4 5,056 58.9 28.9 3,483 80.3 7.8 7,967 52.6 16.2
Cefotaxime 11,283 9.2 50.4 1,836 13.3 47.5 4,181 6.0 70.7 2,689 7.7 52.2 NT NT NT
Ceftazidime 26,353 71.2 17.4 6,036 73.7 13.4 7,640 56.7 31.3 5,141 76.2 14.9 8,547 70.2 14.9
Ceftriaxone 14,066 12.1 56.4 2,847 11.3 59.7 3,383 8.4 70.4 154 26.6 7.8 NT NT NT
Ciprofloxacin 26,700 62.8 33.1 5,924 67.2 30.2 7,388 58.4 38.8 4,746 68.6 24.4 8,560 55.3 40.6
Gentamicin 29,268 69.4 21.5 5,951 72.2 15.9 7,522 52.2 41.7 3,913 74.0 14.3 7,327 44.0 46.1
Imipenem 26,076 73.5 22.1 3,775 77.9 18.2 7,057 59.7 27.8 4,412 70.5 19.0 8,575 69.5 21.4
Levofloxacin 21,059 62.7 31.7 713 56.8 33.5 2,427 44.9 51.0 2,953 68.0 23.9 NT NT NT
Meropenem 7,540 76.0 18.2 1,266 80.3 14.5 4,082 57.3 32.7 4,351 77.8 13.8 1,818 81.1 6.4
Piperacillin 22,855 77.7 22.2 5,520 80.9 18.8 7,004 63.1 36.7 4,554 81.7 14.1 8,454 64.1 24.1
Piperacillin-
tazobactam
21,848 85.5 14.4 4,190 91.0 9.0 5,252 77.7 22.0 4,746 85.8 10.7 8,256 69.6 15.9
Trimethoprim-
sulfamethoxazole
15,618 3.6 96.4 4,283 4.0 96.0 7,054 4.1 95.8 3,375 4.2 95.8 NT NT NT
aNCCLS breakpoints were used for all countries, except France (CA-SFM) bNT = not testedAnnals of Clinical Microbiology and Antimicrobials 2004, 3:14 http://www.ann-clinmicrob.com/content/3/1/14
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e.g.  Klebsiella spp.,P. aeruginosa, and Acinetobacter spp.
present significant therapeutic challenges in ICUs in the
United States. With the exception of cefepime, all other
tested antimicrobials demonstrated >12% resistance to P.
aeruginosa, many considerably higher. Piperacillin-tazo-
bactam showed the next lowest resistance rate, 14.4%,
with all other agents having rates of 17% or higher. Non-
susceptibility to ciprofloxacin among P. aeruginosa was
37.2%, higher than in the Neuberger report. Sahm et al.
reported a 10% increase in fluoroquinolone resistance
among P. aeruginosa in the United States, whereas resist-
ance emerged more slowly with the other classes of anti-
microbials tested [12]. Acinetobacter infections continue to
present significant therapeutic challenges due to the
extensive resistance mechanisms demonstrated by the
>25% resistance shown in Table 5. Only imipenem has
any reliable activity against Acinetobacter spp. with an 87%
susceptibility rate.
There are several implications of these data. It is essential
that local surveillance programs be maintained in each
country's ICU setting. The local data are vital to the formu-
lary committees as they select appropriate agents to treat
infections. There are clear differences among the five
countries studied in this report. Although the predomi-
nant pathogens are similar, ongoing surveillance is essen-
tial to detect the emergence of resistant species. It is clear
that certain classes of compounds are losing activity
against the ICU pathogens tested. For example, the fluor-
oquinolones have reduced susceptibility among many
Gram-negative species as well as staphylococci; however,
the newer class members have enhanced activity against
pneumococci. Advanced-generation cephalosporins have
variable activity, with ceftriaxone showing consistently
good activity against the Enterobacteriaceae and some sta-
phylococci. Ceftazidime has lost potency due to the emer-
gence of ESBL enzymes and also has diminished activity
against P. aeruginosa. Piperacillin-tazobactam is generally
active against P. aeruginosa in ICUs. The aminoglycoside,
gentamicin has shown continued activity against most
Enterobacteriaceae in all five countries, and modest activity
against S. aureus but not against CNS strains. The gen-
tamicin susceptibility of P. aeruginosa ranged from 44.0%
in France to 74.0% in Germany, whereas Acinetobacter spp
. showed more variable gentamicin susceptibility varying
from 23.3% in Italy to 82.0% in Germany. These local
data should be considered when treating infections in the
ICU.
Use of agents with anti-pseudomonal activity such as
cefepime, piperacillin-tazobactam or the carbapenems
should preferably be reserved for patient types or infec-
tions where this pathogen is present or risk factors exist, as
per the ATS Community acquired-pneumonia guidelines
[24]. A combination of a third-generation cephalosporin
such as ceftriaxone with vancomycin may be appropriate
for bloodstream infections based upon the NNIS etiology
data from 1992–1999.
Conclusions
The current study confirmed the emergence of fluoroqui-
nolone resistance among various Gram-negative species
and staphylococci, which may be increasing due to the
heightened use of these drugs; however the reported ESBL
rates among Enterobacteriaceae was lower than noted in
other studies and appeared to be stable. The prevalence of
MRSA, perhaps the most significant resistant hospital
pathogen, varied among the five countries and appeared
to be increasing. Parenteral cephalosporins such as ceftri-
axone and cefotaxime remained quite active against
Enterobacteriaceae. Up-to-date susceptibility data should
be made available as rapidly as possible to physicians so
that appropriate targeted empirical therapy can be insti-
tuted, this approach can assist in maintaining the activity
of the current antimicrobials. While local surveillance
studies remain crucial, national surveillance studies such
as this can provide an invaluable data source to provide
guidance in formulary decision-making.
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